Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2015, Article ID 609593, 6 pages
http://dx.doi.org/10.1155/2015/609593
Research Article

Th1, Th2, and Th17 Cytokine Involvement in Thyroid Associated Ophthalmopathy

1Department of Endocrinology and Metabolism, The Third Affiliated Hospital of Southern Medical University, Guangzhou 510630, China
2Department of Endocrinology and Metabolism, Guangzhou City People’s Hospital, Huadu District, Guangzhou, China
3Department of Endocrinology and Metabolism, Nanjing Jiangning Hospital, Nanjing, China
4Department of Endocrinology and Metabolism, Guangzhou Military General Hospital, Guangzhou, China

Received 5 December 2014; Revised 30 April 2015; Accepted 30 April 2015

Academic Editor: Giuseppe Murdaca

Copyright © 2015 Jie Shen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. S. Bahn, “Graves' ophthalmopathy,” The New England Journal of Medicine, vol. 362, no. 8, pp. 726–774, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. K. P. Cockerham and S. S. Chan, “Thyroid Eye Disease,” Neurologic Clinics, vol. 28, no. 3, pp. 729–755, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. F. Menconi, C. Marcocci, and M. Marinò, “Diagnosis and classification of Graves' disease,” Autoimmunity Reviews, vol. 13, no. 4-5, pp. 398–402, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. L. Bartalena, “Diagnosis and management of Graves disease: a global overview,” Nature Reviews Endocrinology, vol. 9, no. 12, pp. 724–734, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. M. N. Stan, J. A. Garrity, and R. S. Bahn, “The evaluation and treatment of graves ophthalmopathy,” Medical Clinics of North America, vol. 96, no. 2, pp. 311–328, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Yang and P. Perros, “Management plan and delivery of care in Graves' ophthalmopathy patients,” Best Practice and Research: Clinical Endocrinology and Metabolism, vol. 26, no. 3, pp. 303–311, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. Y. Wang and T. J. Smith, “Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy,” Investigative Ophthalmology and Visual Science, vol. 55, no. 3, pp. 1735–1748, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. H. Stiebel-Kalish, E. Robenshtok, and D. D. Gaton, “Pathophysiology of Graves' ophthalmopathy,” Pediatric Endocrinology Reviews, vol. 7, supplement 2, pp. 178–181, 2010. View at Google Scholar · View at Scopus
  9. R. S. Douglas and S. Gupta, “The pathophysiology of thyroid eye disease: implications for immunotherapy,” Current Opinion in Ophthalmology, vol. 22, no. 5, pp. 385–390, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. V. Naik, N. Khadavi, M. N. Naik et al., “Biologic therapeutics in thyroid-associated ophthalmopathy: translating disease mechanism into therapy,” Thyroid, vol. 18, no. 9, pp. 967–971, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. T. J. Smith, “The putative role of fibroblasts in the pathogenesis of Graves' disease: evidence for the involvement of the insulin-like growth factor-1 receptor in fibroblast activation,” Autoimmunity, vol. 36, no. 6-7, pp. 409–415, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. D. Song, R. Wang, Y. Zhong et al., “Locally produced insulin-like growth factor-1 by orbital fibroblasts as implicative pathogenic factor rather than systemically circulated IGF-1 for patients with thyroid-associated ophthalmopathy,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 250, no. 3, pp. 433–440, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. T. J. Smith, L. Hegedüs, and R. S. Douglas, “Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves' orbitopathy,” Best Practice and Research: Clinical Endocrinology and Metabolism, vol. 26, no. 3, pp. 291–302, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. A. G. Gianoukakis, N. Khadavi, and T. J. Smith, “Cytokines, graves' disease, and thyroid-associated ophthalmopathy,” Thyroid, vol. 18, no. 9, pp. 953–958, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. T. K. Khoo and R. S. Bahn, “Pathogenesis of Graves' ophthalmopathy: the role of autoantibodies,” Thyroid, vol. 17, no. 10, pp. 1013–1018, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. T. Bednarczuk, Y. Hiromatsu, Y. Inoue, K. Yamamoto, J. R. Wall, and J. Nauman, “T-cell-mediated immunity in thyroid-associated ophthalmopathy,” Thyroid, vol. 12, no. 3, pp. 209–215, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Pappa, J. M. M. Lawson, V. Calder, P. Fells, and S. Lightman, “T cells and fibroblasts in affected extraocular muscles in early and late thyroid associated ophthalmopathy,” British Journal of Ophthalmology, vol. 84, no. 5, pp. 517–522, 2000. View at Publisher · View at Google Scholar · View at Scopus
  18. D. Yang, Y. Hiromatsu, T. Hoshino, Y. Inoue, K. Itoh, and K. Nonaka, “Dominant infiltration of TH1-type CD4+ T cells at the retrobulbar space of patients with thyroid-associated ophthalmopathy,” Thyroid, vol. 9, no. 3, pp. 305–310, 1999. View at Publisher · View at Google Scholar · View at Scopus
  19. G. del Prete, “The concept of type-1 and type-2 helper T cells and their cytokines in humans,” International Reviews of Immunology, vol. 16, no. 3-4, pp. 427–455, 1998. View at Publisher · View at Google Scholar · View at Scopus
  20. P. Kidd, “Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease,” Alternative Medicine Review, vol. 8, no. 3, pp. 223–246, 2003. View at Google Scholar · View at Scopus
  21. F. Esfahanian, E. Naimi, F. Doroodgar, and Z. Jadali, “Th1/Th2 cytokines in patients with graves' disease with or without ophthalmopathy,” Iranian Journal of Allergy, Asthma and Immunology, vol. 12, no. 2, pp. 168–175, 2013. View at Google Scholar · View at Scopus
  22. I. M. M. J. Wakelkamp, M. N. Gerding, J. W. C. Van Der Meer, M. F. Prummel, and W. M. Wiersinga, “Both Th1- and Th2-derived cytokines in serum are elevated in Graves' ophthalmopathy,” Clinical and Experimental Immunology, vol. 121, no. 3, pp. 453–457, 2000. View at Publisher · View at Google Scholar · View at Scopus
  23. S. K. Bedoya, B. Lam, K. Lau, and J. Larkin III, “Th17 cells in immunity and autoimmunity,” Clinical and Developmental Immunology, vol. 2013, Article ID 986789, 16 pages, 2013. View at Publisher · View at Google Scholar
  24. T. Nanba, M. Watanabe, N. Inoue, and Y. Iwatani, “Increases of the Th1/Th2 cell ratio in severe Hashimoto's disease and in the proportion of Th17 cells in intractable Graves' disease,” Thyroid, vol. 19, no. 5, pp. 495–501, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. H. Wei, M. Guan, Y. Qin et al., “Circulating levels of miR-146a and IL-17 are significantly correlated with the clinical activity of Graves' ophthalmopathy,” Endocrine Journal, vol. 61, no. 11, pp. 1087–1092, 2014. View at Publisher · View at Google Scholar
  26. S. E. Kim, J. S. Yoon, K. H. Kim, and S. Y. Lee, “Increased serum interleukin-17 in Graves' ophthalmopathy,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 250, no. 10, pp. 1521–1526, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. M. P. Mourits, L. Koornneef, W. M. Wiersinga, M. F. Prummel, A. Berghout, and R. van der Gaag, “Clinical criteria for the assessment of disease activity in Graves' ophthalmology: a novel approach,” British Journal of Ophthalmology, vol. 73, no. 8, pp. 639–644, 1989. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Leung, X. Liu, L. Fang, X. Chen, T. Guo, and J. Zhang, “The cytokine milieu in the interplay of pathogenic Th1/Th17 cells and regulatory T cells in autoimmune disease,” Cellular and Molecular Immunology, vol. 7, no. 3, pp. 182–189, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. R. Pappu, V. Ramirez-Carrozzi, N. Ota, W. Ouyang, and Y. Hu, “The IL-17 family cytokines in immunity and disease,” Journal of Clinical Immunology, vol. 30, no. 2, pp. 185–195, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. J. F. Zambrano-Zaragoza, E. J. Romo-Martínez, M. d. Durán-Avelar, N. García-Magallanes, and N. Vibanco-Pérez, “Th17 cells in autoimmune and infectious diseases,” International Journal of Inflammation, vol. 2014, Article ID 651503, 12 pages, 2014. View at Publisher · View at Google Scholar
  31. G. Kleiner, A. Marcuzzi, V. Zanin, L. Monasta, and G. Zauli, “Cytokine levels in the serum of healthy subjects,” Mediators of Inflammation, vol. 2013, Article ID 434010, 6 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. O. Arican, M. Aral, S. Sasmaz, and P. Ciragil, “Serum levels of TNF-α, IFN-γ, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity,” Mediators of Inflammation, vol. 2005, no. 5, pp. 273–279, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. W. Wanachiwanawin, E. Wiener, U. Siripanyaphinyo et al., “Serum levels of tumor necrosis factor-alpha, interleukin-1, and interferon-gamma in beta(o)-thalassemia/HbE and their clinical significance,” Journal of Interferon & Cytokine Research, vol. 19, no. 2, pp. 105–111, 1999. View at Google Scholar
  34. P. Tang, L. Chong, X. Li et al., “Correlation between serum RANTES levels and the severity of Parkinson's disease,” Oxidative Medicine and Cellular Longevity, vol. 2014, Article ID 208408, 4 pages, 2014. View at Publisher · View at Google Scholar
  35. F. Nicoletti, F. Patti, R. Di Marco et al., “Circulating serum levels of IL-1ra in patients with relapsing remitting multiple sclerosis are normal during remission phases but significantly increased either during exacerbations or in response to IFN-β treatment,” Cytokine, vol. 8, no. 5, pp. 395–400, 1996. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Robati, A. Ranjbari, M. G. Boroujerdnia, and Z. Chinipardaz, “Detection of IL-4, IL-6 and IL-12 serum levels in generalized aggressive periodontitis,” Iranian Journal of Immunology, vol. 8, no. 3, pp. 170–175, 2011. View at Google Scholar · View at Scopus
  37. L. Wang, W. Teng, and Z. Shan, “Effect of IFN-γ, IL-4 on proliferation and synthesis of hyaluronic acid and collagen in cultured human retroorbital fibroblasts in vitro,” Chinese Medical Journal, vol. 113, no. 10, pp. 907–910, 2000. View at Google Scholar · View at Scopus
  38. A. Antonelli, M. Rotondi, S. M. Ferrari et al., “Interferon-gamma-inducible alpha-chemokine CXCL10 involvement in Graves' ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 2, pp. 614–620, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. R. W. Valyasevi, S. C. Jyonouchi, C. M. Dutton, N. Munsakul, and R. S. Bahn, “Effect of tumor necrosis factor-α, interferon-γ, and transforming growth factor-β on adipogenesis and expression of thyrotropin receptor in human orbital preadipocyte fibroblasts,” Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 2, pp. 903–908, 2001. View at Publisher · View at Google Scholar · View at Scopus
  40. A. Antonelli, S. M. Ferrari, P. Fallahi et al., “Monokine induced by interferon gamma (IFNgamma) (CXCL9) and IFNgamma inducible T-cell alpha-chemoattractant (CXCL11) involvement in Graves' disease and ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists,” Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 5, pp. 1803–1809, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. K. Yamamoto, M. Itoh, T. Okamura et al., “Relative levels of the inflammatory cytokine TNFα and the soluble CD40 ligand profile in serum correlate with the thyrotoxic activity of Graves' disease,” Thyroid, vol. 22, no. 5, pp. 516–521, 2012. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Salvi, M. Pedrazzoni, G. Girasole et al., “Serum concentrations of proinflammatory cytokines in Graves' disease: effect of treatment, thyroid function, ophthalmopathy and cigarette smoking,” European Journal of Endocrinology, vol. 143, no. 2, pp. 197–202, 2000. View at Publisher · View at Google Scholar · View at Scopus
  43. A. B. B. Pedro, J. H. Romaldini, and K. Takei, “Changes of serum cytokines in hyperthyroid graves' disease patients at diagnosis and during methimazole treatment,” NeuroImmunoModulation, vol. 18, no. 1, pp. 45–51, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. J. Myśliwiec, A. Krȩtowski, J. Topolska et al., “Serum Th1 and Th2 profile cytokine level changes in patients with Graves' ophthalmopathy treated with corticosteroids,” Hormone and Metabolic Research, vol. 33, no. 12, pp. 739–743, 2001. View at Publisher · View at Google Scholar · View at Scopus
  45. J. Mysliwiec, I. Palyga, A. Nikolajuk, A. Kowalska, and M. Gorska, “Serum interleukin-16 and RANTES during treatment of Graves' orbitopathy with corticosteroids and teleradiotherapy,” Endokrynologia Polska, vol. 63, no. 2, pp. 92–96, 2012. View at Google Scholar · View at Scopus